​

NewAmsterdam Pharma (NAMS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NAMS Stock Forecast

NewAmsterdam Pharma (NAMS) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $49.75, with a high of $58.00 and a low of $45.00. This represents a 67.85% increase from the last price of $29.64.

$10 $20 $30 $40 $50 $60 High: $58 Avg: $49.75 Low: $45 Last Closed Price: $29.64

NAMS Stock Rating

NewAmsterdam Pharma stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

NAMS Price Target Upside V Benchmarks

TypeNameUpside
StockNewAmsterdam Pharma67.85%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts339
Avg Price Target$51.33$51.33$48.33
Last Closing Price$29.64$29.64$29.64
Upside/Downside73.18%73.18%63.06%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 263101--14
Jun, 263101--14
May, 263111--15
Apr, 262111--14
Mar, 262101--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 20, 2026BMO Capital$58.00$29.6795.48%95.68%
Jul 20, 2026Dennis DingJefferies$45.00$29.7451.31%51.82%
Jun 30, 2026RBC Capital$51.00$33.8750.58%72.06%
Feb 19, 2026Guggenheim$45.00$35.7625.84%51.82%
Jan 21, 2026RBC Capital$47.00$32.4145.02%58.57%
Jan 06, 2026Roanna RuizLeerink Partners$55.00$33.4864.28%85.56%
Dec 02, 2025Goldman Sachs$37.00$39.61-6.59%24.83%
Oct 20, 2025Joseph PantginisH.C. Wainwright$52.00$36.4042.86%75.44%
Aug 25, 2025Wells Fargo$45.00$24.7082.19%51.82%
Mar 03, 2025UBS$41.00$20.27102.27%38.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 20, 2026BMO CapitalOutperforminitialise
Jul 20, 2026JefferiesBuyBuyhold
Jun 30, 2026RBC CapitalOutperformOutperformhold
Feb 19, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 19, 2026GuggenheimBuyBuyhold
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 06, 2026Leerink PartnersOutperformOutperformhold
Dec 02, 2025Goldman SachsNeutralNeutralhold
Oct 17, 2025CitigroupBuyBuyhold
Aug 25, 2025Wells FargoOverweightinitialise

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.11$-2.15$-2.56$-1.72---
Avg Forecast$0.17$-1.95$-1.96$-1.76$-1.64$-1.24$-0.09
High Forecast$0.19$-1.88$-1.73$-1.23$-0.20$-0.15$-0.01
Low Forecast$0.10$-2.05$-2.05$-2.16$-3.08$-2.32$-0.17
Surprise %-752.94%10.26%30.61%-2.27%---

Revenue Forecast

$0 $130M $260M $390M $520M $650M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$102.69M$14.09M$45.56M$22.50M---
Avg Forecast$104.94M$13.08M$33.77M$9.01M$20.55M$141.91M$369.24M
High Forecast$110.13M$14.21M$37.06M$15.07M$34.39M$237.47M$617.87M
Low Forecast$98.37M$11.37M$31.40M$2.94M$6.71M$46.35M$120.61M
Surprise %-2.14%7.74%34.91%149.85%---

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.63M$-176.94M$-241.60M----
Avg Forecast$13.66M$-160.47M$-161.18M$-144.40M$-134.76M$-101.59M$-7.47M
High Forecast$15.68M$-154.47M$-142.40M$-100.84M$-16.80M$-12.66M$-931.39K
Low Forecast$8.14M$-168.72M$-168.22M$-177.47M$-252.72M$-190.52M$-14.02M
Surprise %-265.68%10.26%49.90%----

NAMS Forecast FAQ

Is NewAmsterdam Pharma stock a buy?

NewAmsterdam Pharma stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that NewAmsterdam Pharma is a favorable investment for most analysts.

What is NewAmsterdam Pharma's price target?

NewAmsterdam Pharma's price target, set by 10 Wall Street analysts, averages $49.75 over the next 12 months. The price target range spans from $45 at the low end to $58 at the high end, suggesting a potential 67.85% change from the previous closing price of $29.64.

How does NewAmsterdam Pharma stock forecast compare to its benchmarks?

NewAmsterdam Pharma's stock forecast shows a 67.85% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for NewAmsterdam Pharma over the past three months?

  • July 2026: 21.43% Strong Buy, 71.43% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 21.43% Strong Buy, 71.43% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 20.00% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.

What is NewAmsterdam Pharma’s EPS forecast?

NewAmsterdam Pharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.64, marking a -4.65% decrease from the reported $-1.72 in 2025. Estimates for the following years are $-1.24 in 2027, and $-0.09 in 2028.

What is NewAmsterdam Pharma’s revenue forecast?

NewAmsterdam Pharma's average annual revenue forecast for its fiscal year ending in December 2026 is $20.55M, reflecting a -8.68% decrease from the reported $22.5M in 2025. The forecast for 2027 is $141.91M, and $369.24M for 2028.

What is NewAmsterdam Pharma’s net income forecast?

NewAmsterdam Pharma's net income forecast for the fiscal year ending in December 2026 stands at $-135M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-102M in 2027, and $-7.473M in 2028.